Home Cart 0 Sign in  
X

[ CAS No. 5437-98-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 5437-98-9
Chemical Structure| 5437-98-9
Chemical Structure| 5437-98-9
Structure of 5437-98-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5437-98-9 ]

Related Doc. of [ 5437-98-9 ]

Alternatived Products of [ 5437-98-9 ]

Product Details of [ 5437-98-9 ]

CAS No. :5437-98-9 MDL No. :MFCD00008783
Formula : C11H13NO3 Boiling Point : -
Linear Structure Formula :- InChI Key :SWAJJKROCOJICG-UHFFFAOYSA-N
M.W : 207.23 Pubchem ID :21576
Synonyms :

Calculated chemistry of [ 5437-98-9 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.27
Num. rotatable bonds : 5
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 57.06
TPSA : 55.4 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.55 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.58
Log Po/w (XLOGP3) : 1.43
Log Po/w (WLOGP) : 1.42
Log Po/w (MLOGP) : 0.89
Log Po/w (SILICOS-IT) : 1.67
Consensus Log Po/w : 1.4

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.99
Solubility : 2.11 mg/ml ; 0.0102 mol/l
Class : Very soluble
Log S (Ali) : -2.2
Solubility : 1.31 mg/ml ; 0.00633 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.27
Solubility : 0.111 mg/ml ; 0.000535 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.25

Safety of [ 5437-98-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 5437-98-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5437-98-9 ]
  • Downstream synthetic route of [ 5437-98-9 ]

[ 5437-98-9 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 141-97-9 ]
  • [ 104-94-9 ]
  • [ 5437-98-9 ]
YieldReaction ConditionsOperation in experiment
73% at 120℃; for 2 h; Green chemistry General procedure: To a stirred solution of amine (0.01 mol) in 10 ml of PEG-300 was added to ethylacetoacatate (0.03 mol) in100 ml round bottom flask and refluxed at 120 C for 1.5–2 h. After completion of the reaction (monitored by TLC) the reaction mixture was cooled and extracted with cold diethyl ether (3 × 10 mL) and purified by column chromatography (10–25percent EtOAc in Hexane) gave the pure product 3a–p. Final products were confirmed with the reported literature.
32% for 24 h; Reflux; Neat (no solvent) General procedure: A mixture of ethylacetoacetate 5 (10.0 g, 76.8 mmol) and aniline 6a (7.0 mL, 76.8 mmol) were taken into a round bottom flask and refluxed under stirring for 24 h. The mixture was concentrated under vacuum and then the crude product was purified by column chromatography using EtOAc:hexane to give acetoacetanilide 8a as white crystalline solid in 42percent yield.
Reference: [1] Synthetic Communications, 2000, vol. 30, # 20, p. 3709 - 3718
[2] Heterocycles, 2008, vol. 75, # 11, p. 2681 - 2701
[3] European Journal of Organic Chemistry, 2015, vol. 2015, # 14, p. 3171 - 3177
[4] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 13, p. 1639 - 1641
[5] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 187 - 195
[6] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 187 - 195
[7] Journal of Organic Chemistry, 2015, vol. 80, # 2, p. 1025 - 1033
[8] Journal of the Indian Chemical Society, 1994, vol. 71, # 10, p. 637 - 640
[9] Journal of Organic Chemistry, 2013, vol. 78, # 11, p. 5385 - 5392
[10] Medicinal Chemistry Research, 2010, vol. 19, # 4, p. 344 - 363
[11] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 8, p. 2708 - 2711
[12] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 22, p. 8035 - 8043
[13] Chemische Berichte, 1931, vol. 64, p. 969
[14] Journal of Organic Chemistry, 1946, vol. 11, p. 803,806,807
[15] Pr.roy.Soc.<B>, 1938, vol. 125, p. 60,84
[16] Gazzetta Chimica Italiana, 1932, vol. 62, p. 14,17
[17] Journal of the Society of Dyers and Colourists, 1939, vol. 55, p. 449,451
[18] Bulletin de la Societe Chimique de France, 1972, p. 637 - 645
[19] Journal of Heterocyclic Chemistry, 1980, vol. 17, # 6, p. 1213 - 1214
[20] International Journal of Chemical Kinetics, 2007, vol. 39, # 2, p. 82 - 91
[21] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 4, p. 698 - 701
[22] European Journal of Medicinal Chemistry, 2008, vol. 43, # 10, p. 2103 - 2115
[23] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 11, p. 4085 - 4094
[24] European Journal of Organic Chemistry, 2011, # 13, p. 2542 - 2547
[25] Journal of Medicinal Chemistry, 2015, vol. 58, # 20, p. 8166 - 8181
[26] Chinese Chemical Letters, 2016, vol. 27, # 3, p. 375 - 379
[27] Chemical Biology and Drug Design, 2015, vol. 85, # 2, p. 201 - 207
[28] Journal of Heterocyclic Chemistry, 2016, vol. 53, # 6, p. 1843 - 1851
[29] Journal of the Chilean Chemical Society, 2017, vol. 62, # 1, p. 3354 - 3358
  • 2
  • [ 5394-63-8 ]
  • [ 104-94-9 ]
  • [ 5437-98-9 ]
Reference: [1] RSC Advances, 2015, vol. 5, # 87, p. 70915 - 70928
[2] Drug Design, Development and Therapy, 2017, vol. 11, p. 407 - 418
[3] Chemical and Pharmaceutical Bulletin, 1989, vol. 37, # 11, p. 2952 - 2960
[4] Journal of the American Chemical Society, 2014, vol. 136, # 14, p. 5267 - 5270
  • 3
  • [ 674-82-8 ]
  • [ 104-94-9 ]
  • [ 5437-98-9 ]
Reference: [1] Medicinal Chemistry Research, 2013, vol. 22, # 4, p. 1563 - 1569
[2] Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 2, p. 365 - 374
[3] Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 2, p. 365 - 374
[4] Journal of the American Chemical Society, 1946, vol. 68, p. 644,645
[5] Bulletin of the Chemical Society of Japan, 1963, vol. 36, p. 492 - 500
  • 4
  • [ 104-94-9 ]
  • [ 5437-98-9 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 3, p. 1493 - 1501
  • 5
  • [ 104-94-9 ]
  • [ 105-45-3 ]
  • [ 5437-98-9 ]
Reference: [1] European Journal of Organic Chemistry, 2009, # 14, p. 2283 - 2288
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 5437-98-9 ]

Tafenoquine Related Intermediates

Chemical Structure| 110-15-6

[ 110-15-6 ]

Succinic acid

Chemical Structure| 91-16-7

[ 91-16-7 ]

1,2-Dimethoxybenzene

Chemical Structure| 1074-82-4

[ 1074-82-4 ]

Potassium 1,3-dioxoisoindolin-2-ide

Chemical Structure| 98-17-9

[ 98-17-9 ]

3-(Trifluoromethyl)phenol

Chemical Structure| 366-99-4

[ 366-99-4 ]

3-Fluoro-4-methoxyaniline